Can You Actually Prevent Alzheimer's? What Longevity Science Says in 2026
By Dr Elena Seranova, PhD (Stem Cell Biology), Founder of NMN Bio
No supplement prevents Alzheimer's. No supplement has been shown to prevent Alzheimer's. This needs stating plainly before going any further.
What the evidence does support is something almost as important: that multiple modifiable biological factors significantly influence when and whether the disease becomes clinically apparent, and that acting on those factors in your 40s and 50s changes the trajectory in meaningful ways.
Alzheimer's is not a disease you get. It is a process that runs for 20 years before you know about it. Understanding that timeline changes everything about how you respond to it.
The 20-year preclinical phase
Jack et al. (2010, Nature Reviews Neuroscience) described the biomarker timeline for Alzheimer's disease in what became the field's most cited framework. Amyloid beta begins accumulating in the brain decades before any cognitive symptom appears. Tau pathology follows. Neurodegeneration follows that. Cognitive symptoms appear last, after years of progressive neuronal damage.
The A4 Study, which screened cognitively normal adults in their 60s and 70s for amyloid positivity via PET imaging, found that a significant proportion showed substantial amyloid deposition with no symptoms whatsoever. The PREVENT Dementia project in the UK found similar early accumulation in adults in their late 40s and early 50s.
The practical implication is stark. By the time of an Alzheimer's diagnosis, the disease has typically been progressing for 15 to 25 years. If you are in your mid-40s and waiting for a symptom before you think about intervention, you may already be in the preclinical phase.
This is not a reason for panic. Amyloid positivity at midlife does not mean inevitable dementia. It means the conditions for pathology are being established, and those conditions are substantially modifiable.
What the best available trial evidence shows
The FINGER trial (Ngandu et al., 2015, The Lancet) is the most important clinical dataset on cognitive decline prevention to date. It enrolled 1,260 older adults at elevated risk of cognitive decline and randomised them to a multi-domain lifestyle intervention or standard care.
The intervention group received: a structured nutrition programme, aerobic exercise, strength training, cognitive training, and intensive monitoring and management of metabolic risk factors (blood pressure, blood glucose, cholesterol, body weight).
After two years, the intervention group showed 31 per cent better cognitive performance compared to controls on a comprehensive neuropsychological battery. Executive function improved 83 per cent more. Processing speed improved 150 per cent more.
No drug has ever produced comparable results in a comparable population.
The FINGER trial succeeded because it addressed multiple modifiable drivers of cognitive decline simultaneously. This is the approach the evidence supports: not a single intervention, but a coordinated protocol targeting the biological substrate.
The modifiable risk factors
The 2020 Lancet Commission on dementia prevention identified 12 modifiable risk factors that together account for approximately 40 per cent of dementia cases worldwide. The factors span the lifespan and include:
- Physical inactivity
- Hypertension
- Type 2 diabetes and metabolic dysfunction
- Obesity
- Depression
- Hearing loss
- Social isolation
- Smoking
- Excessive alcohol
- Traumatic brain injury
- Air pollution
- Low education
The common thread is that each factor either increases neuroinflammation, reduces cerebral blood flow, impairs sleep quality, or degrades metabolic function. All are mechanisms that accelerate the amyloid accumulation and neuronal energy failure that define the disease.
Two factors not yet in the 2020 Lancet report but with strong mechanistic support:
NAD+ status. NAD+ depletion reduces neuronal energy supply, impairs sirtuin-mediated DNA repair and neuroprotection, and decreases BDNF production via the SIRT1 axis. Stein and Imai (2014) demonstrated that NMN reversed cognitive decline in a mouse model of Alzheimer's-related neurodegeneration. Yao et al. (2022) showed NMN improved spatial memory and reduced neuroinflammation in aged mice. Human cognitive trials on NMN are ongoing; the mechanistic case is established.
Sleep quality and glymphatic function. Chronic poor sleep impairs glymphatic clearance of amyloid beta. Holth et al. (2019, Science) showed that a single night of sleep deprivation measurably raises CSF amyloid in healthy humans. Magnesium deficiency, by suppressing deep sleep architecture, contributes to this pathway directly.
What this means for supplementation
No supplement prevents Alzheimer's. What supplementation can do is address the specific biological deficits that are modifiable risk factors for the disease.
Restoring NAD+ availability addresses the cellular energy deficit that drives neuronal dysfunction and reduces SIRT1-mediated neuroprotection. It is not a cure or a prevention. It is the correction of a documented age-related decline that worsens one of the most important modifiable risk factors.
Supporting deep sleep quality protects glymphatic function, the brain's mechanism for removing amyloid beta nightly. Magnesium deficiency suppresses deep sleep and is extremely common in adults on a typical Western diet.
These two interventions target different layers of the same underlying problem: neurons that are underpowered and under-maintained.
Morning: NAD+ Brain. Citicoline, phosphatidylserine, L-theanine, L-tyrosine, fisetin, apigenin, and B vitamins. The cellular energy and neurotransmitter support layer for daytime cognitive function.
Evening: Oh!Mg. Bioavailable magnesium forms (bisglycinate, taurate, lactate), lemon balm, L-theanine, melatonin cofactors. The deep sleep architecture and overnight glymphatic clearance layer.
The Day and Night Bundle is the complete morning-evening protocol.
These sit alongside, not instead of, the lifestyle fundamentals: exercise, metabolic health, stress management, social connection.
Frequently Asked Questions
Can lifestyle changes actually prevent Alzheimer's?
The FINGER trial is the strongest evidence that a multi-domain lifestyle intervention can significantly slow cognitive decline in high-risk adults. It does not prove that Alzheimer's can be prevented entirely. It demonstrates that the rate of decline is substantially modifiable through targeted intervention. The effect size (31% better cognitive performance at two years) is larger than any drug trial in this space.
Is Alzheimer's genetic?
Most Alzheimer's is not caused by a single gene. The APOE4 variant is the strongest genetic risk factor, carried by approximately 25 per cent of the population. Having one copy of APOE4 increases Alzheimer's risk roughly threefold. Having two copies increases it roughly 12-fold. But 60 per cent of Alzheimer's patients do not carry APOE4 at all. The vast majority of cases are influenced by the interaction of multiple genes and, critically, by modifiable lifestyle and metabolic factors.
When should I start thinking about cognitive decline prevention?
The preclinical phase of Alzheimer's begins in the 40s and 50s for many people. The ideal window for primary prevention is before pathological accumulation begins. That means the 40s are the most important decade, not retirement. If you are over 40 and not taking any active steps to preserve cognitive function, you are working with a closing window.
Do supplements interact with dementia medications?
None of the ingredients in NAD+ Brain or Oh!Mg have known contraindications with common dementia medications (acetylcholinesterase inhibitors such as donepezil). However, if you or a family member are taking prescribed medication for any cognitive condition, confirm with your clinician before adding any supplement protocol.
Can cognitive decline that has already started be slowed?
Yes. Even at the MCI (mild cognitive impairment) stage, the underlying biology is still substantially modifiable. Addressing NAD+ depletion, sleep quality, exercise, and metabolic health can measurably improve cognitive function in people with MCI. The earlier the intervention, the greater the potential benefit, but late is still better than never.
The bottom line
Alzheimer's is not an event. It is a 20-year process. The modifiable risk factors for its progression are documented, well-studied, and actionable now.
No supplement prevents it. What the evidence supports is addressing the specific biological deficits, particularly NAD+ status and sleep quality, that modifiable research has linked most directly to neurodegeneration risk.
The decade to act is your 40s. The window does not stay open indefinitely.
Leave a comment